Meridian Bioscience was founded in 1977 and is headquartered in Cincinnati, US

Meridian Bioscience has an office in Cincinnati

Cincinnati, US (HQ)

3471 River Hills Dr

Meridian Bioscience's revenue was reported to be $196.1 m in 2016 which is a **1% increase** from the previous period.

Numbers are in $, USD

## Revenue (Y, 2016) | 196.1 m |

## Revenue growth (Y, 2015 - Y, 2016), % | 1% |

## Gross profit (Y, 2016) | 127.8 m |

## Gross profit margin (Y, 2016), % | 65% |

## Net income (Y, 2016) | 32.2 m |

## EBIT (Y, 2016) | 51.4 m |

## Market capitalization (26-May-2017) | 584.5 m |

## Closing share price (26-May-2017) | 14 |

## Cash (30-Sep-2016) | 47.2 m |

## EV | 595.6 m |

Meridian Bioscience's current market capitalization is $584.5 m.

Numbers are in $, USD | Y, 2013^{} | Y, 2014^{} | Y, 2015^{} | Y, 2016^{} |
---|---|---|---|---|

## Revenue | 188.7 m | 188.8 m | 194.8 m | 196.1 m |

## Revenue growth, % | 0% | 3% | 1% | |

## Cost of goods sold | 67.6 m | 71.6 m | 72.9 m | 68.3 m |

## Gross profit | 121 m | 117.2 m | 121.9 m | 127.8 m |

## Gross profit Margin, % | 64% | 62% | 63% | 65% |

## Operating expense total | 63.7 m | 64.9 m | 65.8 m | 76.4 m |

## EBIT | 57.3 m | 52.4 m | 56.1 m | 51.4 m |

## EBIT margin, % | 30% | 28% | 29% | 26% |

## Interest expense | 897 k | |||

## Interest income | 44 k | 25 k | 23 k | 67 k |

## Pre tax profit | 57.4 m | 52.1 m | 55.1 m | 50.6 m |

## Income tax expense | 19.3 m | 17.4 m | 19.5 m | 18.4 m |

## Net Income | 38 m | 34.7 m | 35.5 m | 32.2 m |

Numbers are in $, USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 44.3 m | 43 m | 50 m | 47.2 m |

## Accounts Receivable | ||||

## Inventories | 34.8 m | 35.5 m | 35.8 m | 45.1 m |

## Current Assets | 114.1 m | 112.7 m | 122.9 m | 126.8 m |

## Goodwill | 23.1 m | 23.2 m | 22.3 m | 62 m |

## Total Assets | 176.7 m | 176.9 m | 183.3 m | 251.8 m |

## Accounts Payable | 5.6 m | 5 m | 6.6 m | 7.6 m |

## Total Debt | 58.4 m | |||

## Current Liabilities | 21.7 m | 13.7 m | 15.3 m | 22.6 m |

## Non-Current Liabilities | 2.2 m | 2.2 m | 62.8 m | |

## Total Liabilities | 15.9 m | 17.4 m | 85.4 m | |

## Additional Paid-in Capital | 107.4 m | 111.9 m | 117.2 m | 122.4 m |

## Retained Earnings | 46.9 m | 48.9 m | 51.1 m | 49.6 m |

## Total Equity | 155 m | 161 m | 165.9 m | 166.5 m |

## Debt to Equity Ratio | 0.4 x | |||

## Debt to Assets Ratio | 0.2 x | |||

## Financial Leverage | 1.1 x | 1.1 x | 1.1 x | 1.5 x |

Numbers are in $, USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | 38 m | 34.7 m | 35.5 m | 32.2 m |

## Accounts Receivable | ||||

## Inventories | ||||

## Accounts Payable | ||||

## Cash From Operating Activities | 44.4 m | 38.3 m | 42.8 m | 37.2 m |

## Purchases of PP&E | (3.2 m) | (5.3 m) | (4.6 m) | (4 m) |

## Cash From Investing Activities | (3.3 m) | (7 m) | (3.6 m) | (66.7 m) |

## Dividends Paid | (31.4 m) | (32.8 m) | (33.4 m) | (33.6 m) |

## Cash From Financing Activities | (28.6 m) | (31.8 m) | (30.7 m) | 27.2 m |

## Interest Paid | 879 k | |||

## Income Taxes Paid | 20.1 m | 20 m | 20.2 m | 17.9 m |

Numbers are in $, USD | Y, 2016 |
---|---|

## EV/EBIT | 11.6 x |

## EV/CFO | 16 x |

## Revenue/Employee | 338.1 k |

## Debt/Equity | 0.4 x |

## Debt/Assets | 0.2 x |

## Financial Leverage | 1.5 x |